Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody
| Class:Id | LiteratureReference:9679785 |
|---|---|
| _displayName | Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody |
| _timestamp | 2020-05-15 12:36:24 |
| author | [Person:9688875] van Rensburg, Anton |
| created | [InstanceEdit:9679866] Jassal, Bijay, 2020-03-25 |
| journal | Drugs R D |
| modified | [InstanceEdit:9688874] Jassal, Bijay, 2020-05-15 |
| pages | 102-7 |
| pubMedIdentifier | 15293871 |
| title | Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody |
| volume | 5 |
| year | 2004 |
| (literatureReference) | [Summation:9685458] Integrins are the receptors that mediate cell adhesion to th... [RegulationReference:9690530] Negative regulation by 'ITGA4:ITGB1:natalizumab [plasma membrane]' Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale [Reaction:9680405] Binding of ITGB1 and natalizumab as Inhibition [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody (9679785)
